Isavuconazole use and TDM in real-world pediatric practice

Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0082923. doi: 10.1128/aac.00829-23. Epub 2023 Nov 14.

Abstract

Isavuconazole (ISA) is approved for treating invasive aspergillosis and mucormycosis in adults, but its use in children remains off-label. We report on the use of ISA in real-world pediatric practice with 15 patients receiving ISA for treatment of invasive fungal infections. Therapeutic drug monitoring (TDM) was performed in all patients, with 52/111 (46.8%) Ctrough determinations out of range, thus supporting the need for TDM in children, especially those receiving extracorporeal membrane oxygenation (ECMO).

Keywords: ECMO; children; invasive fungal infection; isavuconazole; targeted drug monitoring.

MeSH terms

  • Adult
  • Antifungal Agents / therapeutic use
  • Aspergillosis* / drug therapy
  • Child
  • Drug Monitoring
  • Humans
  • Invasive Fungal Infections* / drug therapy
  • Nitriles / therapeutic use
  • Triazoles / therapeutic use

Substances

  • isavuconazole
  • Antifungal Agents
  • Triazoles
  • Nitriles